PMC:7205724 / 22937-23259
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
808 | 251-254 | Gene | denotes | IL6 | Gene:3569 |
809 | 63-71 | Species | denotes | patients | Tax:9606 |
810 | 160-168 | Species | denotes | patients | Tax:9606 |
811 | 38-49 | Chemical | denotes | tocilizumab | MESH:C502936 |
812 | 129-140 | Chemical | denotes | Tocilizumab | MESH:C502936 |
813 | 97-105 | Disease | denotes | COVID-19 | MESH:C000657245 |
814 | 174-182 | Disease | denotes | COVID-19 | MESH:C000657245 |
815 | 209-227 | Disease | denotes | hyper inflammation | MESH:D007249 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T166 | 266-274 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T178 | 97-105 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T179 | 174-182 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T180 | 215-227 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T174 | 38-49 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T23 | 266-281 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | platelet counts | http://purl.bioontology.org/ontology/MEDDRA/10035525 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T219 | 97-105 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T220 | 174-182 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T187 | 0-106 | Sentence | denotes | There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. |
T188 | 107-322 | Sentence | denotes | Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
811 | 38-49 | Chemical | denotes | tocilizumab | MESH:C502936 |
809 | 63-71 | Species | denotes | patients | Tax:9606 |
813 | 97-105 | Disease | denotes | COVID-19 | MESH:C000657245 |
812 | 129-140 | Chemical | denotes | Tocilizumab | MESH:C502936 |
810 | 160-168 | Species | denotes | patients | Tax:9606 |
814 | 174-182 | Disease | denotes | COVID-19 | MESH:C000657245 |
815 | 209-227 | Disease | denotes | hyper inflammation | MESH:D007249 |
808 | 251-254 | Gene | denotes | IL6 | Gene:3569 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T2216 | 251-254 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
T2260 | 256-264 | Protein | denotes | ferritin | https://www.uniprot.org/uniprot/Q26061 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T24269 | 0-5 | EX | denotes | There |
T26765 | 6-9 | VBP | denotes | are |
T84711 | 10-17 | VBG | denotes | ongoing |
T74304 | 18-26 | JJ | denotes | clinical |
T68003 | 27-33 | NNS | denotes | trials |
T5000 | 34-37 | IN | denotes | for |
T64198 | 38-49 | NN | denotes | tocilizumab |
T83078 | 50-59 | NN | denotes | treatment |
T11331 | 60-62 | IN | denotes | in |
T42834 | 63-71 | NNS | denotes | patients |
T27205 | 72-76 | IN | denotes | with |
T23786 | 77-85 | JJ | denotes | moderate |
T45333 | 86-89 | CC | denotes | and |
T9137 | 90-96 | JJ | denotes | severe |
T27842 | 97-105 | NN | denotes | COVID-19 |
T92236 | 107-116 | RB | denotes | Currently |
T32112 | 116-117 | -COMMA- | denotes | , |
T54987 | 118-121 | DT | denotes | the |
T85855 | 122-125 | NN | denotes | use |
T69355 | 126-128 | IN | denotes | of |
T40115 | 129-140 | NNP | denotes | Tocilizumab |
T10850 | 141-143 | VBZ | denotes | is |
T78367 | 144-155 | VBN | denotes | recommended |
T33042 | 156-159 | IN | denotes | for |
T36466 | 160-168 | NNS | denotes | patients |
T61983 | 169-173 | IN | denotes | with |
T2749 | 174-182 | NN | denotes | COVID-19 |
T17580 | 183-186 | WP | denotes | who |
T69055 | 187-191 | VBP | denotes | have |
T71996 | 192-199 | VBG | denotes | warning |
T59356 | 200-205 | NNS | denotes | signs |
T65527 | 206-208 | IN | denotes | of |
T99769 | 209-214 | NN | denotes | hyper |
T44301 | 215-227 | NN | denotes | inflammation |
T54453 | 227-228 | -COMMA- | denotes | , |
T58078 | 229-231 | IN | denotes | as |
T75237 | 232-235 | MD | denotes | can |
T7496 | 236-238 | VB | denotes | be |
T53845 | 239-247 | VBN | denotes | measured |
T78207 | 248-250 | IN | denotes | by |
T88455 | 251-254 | NN | denotes | IL6 |
T77671 | 254-255 | -COMMA- | denotes | , |
T67481 | 256-264 | NN | denotes | ferritin |
T99390 | 264-265 | -COMMA- | denotes | , |
T23484 | 266-274 | NN | denotes | platelet |
T65701 | 275-281 | NNS | denotes | counts |
T30323 | 281-282 | -COMMA- | denotes | , |
T72053 | 283-295 | JJ | denotes | inflammatory |
T81575 | 296-303 | NNS | denotes | markers |
T96428 | 303-304 | -COMMA- | denotes | , |
T36542 | 305-308 | CC | denotes | and |
T88469 | 309-310 | NN | denotes | H |
T51141 | 311-316 | NN | denotes | score |
T97739 | 317-318 | -LRB- | denotes | [ |
T29313 | 318-320 | CD | denotes | 28 |
T54016 | 320-321 | -RRB- | denotes | ] |
R66954 | T24269 | T26765 | arg1Of | There,are |
R94262 | T68003 | T26765 | arg2Of | trials,are |
R16905 | T68003 | T84711 | arg1Of | trials,ongoing |
R34037 | T68003 | T74304 | arg1Of | trials,clinical |
R29518 | T68003 | T5000 | arg1Of | trials,for |
R26554 | T83078 | T5000 | arg2Of | treatment,for |
R27449 | T83078 | T64198 | arg1Of | treatment,tocilizumab |
R95470 | T83078 | T11331 | arg1Of | treatment,in |
R78533 | T42834 | T11331 | arg2Of | patients,in |
R30062 | T42834 | T27205 | arg1Of | patients,with |
R17601 | T27842 | T27205 | arg2Of | COVID-19,with |
R89241 | T27842 | T23786 | arg1Of | COVID-19,moderate |
R28465 | T23786 | T45333 | arg1Of | moderate,and |
R59576 | T9137 | T45333 | arg2Of | severe,and |
R97104 | T27842 | T9137 | arg1Of | COVID-19,severe |
R53041 | T58078 | T92236 | arg1Of | as,Currently |
R61441 | T58078 | T32112 | arg1Of | as,"," |
R66943 | T85855 | T54987 | arg1Of | use,the |
R89881 | T85855 | T69355 | arg1Of | use,of |
R92489 | T40115 | T69355 | arg2Of | Tocilizumab,of |
R4907 | T85855 | T10850 | arg1Of | use,is |
R54223 | T78367 | T10850 | arg2Of | recommended,is |
R26904 | T85855 | T78367 | arg2Of | use,recommended |
R93944 | T78367 | T33042 | arg1Of | recommended,for |
R96954 | T36466 | T33042 | arg2Of | patients,for |
R92720 | T36466 | T61983 | arg1Of | patients,with |
R61251 | T2749 | T61983 | arg2Of | COVID-19,with |
R60119 | T36466 | T17580 | arg1Of | patients,who |
R35135 | T36466 | T69055 | arg1Of | patients,have |
R48731 | T59356 | T69055 | arg2Of | signs,have |
R72772 | T59356 | T71996 | arg1Of | signs,warning |
R6154 | T59356 | T65527 | arg1Of | signs,of |
R22400 | T44301 | T65527 | arg2Of | inflammation,of |
R13264 | T44301 | T99769 | arg1Of | inflammation,hyper |
R72983 | T78367 | T54453 | arg1Of | recommended,"," |
R85482 | T78367 | T58078 | arg1Of | recommended,as |
R94310 | T53845 | T58078 | arg2Of | measured,as |
R71674 | T85855 | T75237 | arg1Of | use,can |
R96842 | T53845 | T75237 | arg2Of | measured,can |
R13154 | T85855 | T7496 | arg1Of | use,be |
R84932 | T53845 | T7496 | arg2Of | measured,be |
R87538 | T85855 | T53845 | arg2Of | use,measured |
R19206 | T53845 | T78207 | arg1Of | measured,by |
R40933 | T36542 | T78207 | arg2Of | and,by |
R89076 | T88455 | T77671 | arg1Of | IL6,"," |
R2282 | T67481 | T77671 | arg2Of | ferritin,"," |
R15531 | T77671 | T99390 | arg1Of | ",","," |
R60586 | T65701 | T99390 | arg2Of | counts,"," |
R8993 | T65701 | T23484 | arg1Of | counts,platelet |
R92565 | T99390 | T30323 | arg1Of | ",","," |
R21977 | T81575 | T30323 | arg2Of | markers,"," |
R92122 | T81575 | T72053 | arg1Of | markers,inflammatory |
R15083 | T36542 | T96428 | arg1Of | and,"," |
R68271 | T30323 | T36542 | arg1Of | ",",and |
R27501 | T51141 | T36542 | arg2Of | score,and |
R83390 | T51141 | T88469 | arg1Of | score,H |
R41615 | T51141 | T97739 | arg1Of | score,[ |
R59110 | T29313 | T97739 | arg2Of | 28,[ |
R77316 | T54016 | T97739 | arg3Of | ],[ |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T32 | 215-227 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T166 | 266-274 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T168 | 97-105 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T169 | 174-182 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T170 | 215-227 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T28 | 215-227 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T28 | 215-227 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T187 | 0-106 | Sentence | denotes | There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. |
T188 | 107-322 | Sentence | denotes | Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]. |